
Clinuvel
CUV.AXClinuvel Pharmaceuticals Limited Price (CUV.AX)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
51,026,713
(1.5232)%Description
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which pr... Read More
Sector: Healthcare
- Previous Close Fetching Data...
- Range $10.89-17.71
- Market Cap 577.20M
- Enterprise Value No Data
- Avg Volume Fetching Data...
- P/E Ratio Fetching Data...
- Dividend Yield Fetching Data...
Industry: Biotechnology
- ceo: Dr. Philippe Jacques Wolgen M.B.A., M.D.
- IPO Date: February, 11, 2001
- Country: AU
- Currency: AUD
- Headquaters: Melbourne, VIC
- Employees: 16
- Revenue from each product or segment:
Product or Segment | Value: | % - Total | Last 3Y: |
---|

- Revenue by Region
Product or Segment | Value: | % - Total | Last 3Y: |
---|
